NDC-11 (Package) (Ascending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
60505-6113-06 | 60505-6113 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6114-00 | 60505-6114 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6115-02 | 60505-6115 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6130-00 | 60505-6130 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | May 26, 2016 | In Use | |
60505-6130-05 | 60505-6130 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | May 26, 2016 | In Use | |
60505-6132-06 | 60505-6132 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 4, 2017 | In Use | |
60505-6132-07 | 60505-6132 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 4, 2017 | In Use | |
60505-6132-08 | 60505-6132 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Nov. 5, 2020 | In Use | |
60505-6166-00 | 60505-6166 | clofarabine | Clofarabine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 1, 2018 | Jan. 31, 2025 | In Use |
60505-6177-08 | 60505-6177 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Aug. 19, 2019 | Jan. 31, 2023 | No Longer Used |
60505-6193-01 | 60505-6193 | Palonosetron Hydrochloride | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sept. 19, 2018 | In Use | |
60505-6228-00 | 60505-6228 | Bendamustine Hydrochloride | Bendamustine Hydrochloride | 25.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | April 26, 2023 | In Use | |
60505-6230-04 | 60505-6230 | Paclitaxel | Paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | April 1, 2022 | In Use | |
60505-6249-01 | 60505-6249 | Dexamethasone | Dexamethasone | 0.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 5, 2023 | In Use | |
60505-6250-01 | 60505-6250 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 5, 2023 | In Use | |
60505-6251-01 | 60505-6251 | Dexamethasone | Dexamethasone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2023 | In Use | |
60505-6252-01 | 60505-6252 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 5, 2023 | In Use | |
60505-6253-01 | 60505-6253 | Dexamethasone | Dexamethasone | 2.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2023 | In Use | |
60505-6254-01 | 60505-6254 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2023 | In Use | |
60505-6255-01 | 60505-6255 | Dexamethasone | Dexamethasone | 6.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 5, 2023 | In Use | |
60505-6271-01 | 60505-6271 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan. 23, 2024 | In Use | |
60505-6272-01 | 60505-6272 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | July 1, 2023 | In Use | |
60505-6277-00 | 60505-6277 | CISplatin | CISplatin | 50.0 mg/50mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 6, 2023 | In Use | |
60505-6279-00 | 60505-6279 | Cisplatin | CISplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 13, 2024 | In Use | |
60505-6287-02 | 60505-6287 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | April 23, 2024 | In Use |
Found 10,000 results in 13 milliseconds — Export these results